A tear in the tubing may prevent users from getting full insulin doses. So far 18 people have reported serious issues related ...

Insulet’s modeled fair value per share has been tweaked from US$354.40 to US$354.12, a very small adjustment that still caught investors’ attention. That subtle move lines up with a research backdrop ...

Insulet estimates that the pods involved in this correction represent approximately 1.5% of annual production globally.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...

OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...

Omnipod 5 has been a major revenue catalyst for Insulet since its release. At the same time, operating expenses associated with Omnipod 5 are higher because of demand exceeding expectations. Higher ...

The correction is related to the Omnipod 5 Controller charging port (USB-C port) or cable (USB cable) melting, deforming, or discoloring. Insulet Corporation has voluntarily issued a Medical Device ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...